Sign In
Buy IMRN
$1.09
-0.0200 (-1.80%)
At Close: Jul 31, 2026
Immuron Director resignation
11:00pm, Thursday, 23'rd Sep 2021
MELBOURNE, Australia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu
Immuron planned Acquisition of R&D Vaccine Company
09:00am, Thursday, 23'rd Sep 2021
MELBOURNE, Australia, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeu
IMM124E – May offer a New modality for Inhibition of SARS-CoV-2
06:00am, Thursday, 13'th May 2021
Key Points
Immuron to Participate in H.C. Wainwright & Co. BioConnect 2021 Virtual Conference
06:00am, Monday, 11'th Jan 2021
MELBOURNE, Australia, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercialising oral immunotherapeut
Immuron SARS-CoV-2 Research Agreement with Monash University
06:00am, Tuesday, 15'th Dec 2020
Key Points
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
06:00am, Wednesday, 11'th Nov 2020
Key Points
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering
04:45pm, Thursday, 23'rd Jul 2020
MELBOURNE, Australia, July 23, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), (the “Company”), an Australian biopharmaceutical company focused on developing and commercializing
Introducing Immuron (ASX:IMC), The Stock That Soared 387% In The Last Year
10:00pm, Wednesday, 22'nd Jul 2020
While stock picking isn't easy, for those willing to persist and learn, it is possible to buy shares in great...
Immuron's stock pulls back but still nearly doubles after stock offering
01:00pm, Tuesday, 21'st Jul 2020
Shares of Immuron Ltd. nearly doubled in premarket trading Tuesday, but pulled back sharply from earlier highs, after the Australia-based biopharmaceutical company announced a registered direct offer
Immuron Announces $20.0 Million Registered Direct Offering
12:45pm, Tuesday, 21'st Jul 2020
MELBOURNE, Australia, July 21, 2020 -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral.
Immuron Reports Neutralizing Activity Against SARS-CoV-2 Key Points
11:00am, Tuesday, 21'st Jul 2020
Immuron’s IMM-124E used to manufacture Travelan® and Protectyn® demonstrates antiviral activity against the COVID-19 virus in laboratory studiesImmuron’s technology platform.
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
10:00am, Monday, 20'th Jul 2020
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted.
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
10:00am, Friday, 19'th Jun 2020
Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc. MELBOURNE, Australia, June 19, 2020 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IM
Price Over Earnings Overview: Immuron
02:29pm, Monday, 15'th Jun 2020
In the current session, Immuron Inc. (NASDAQ: IMRN) is trading at $10.30, after a 20.06% spike. Over the past month, the stock increased by 412.50%, and in the past year, by 248.01%. With performance
The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset
11:30am, Wednesday, 10'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 9) * Dr.Reddy's Laboratories Ltd (NYSE: RDY) * Imara Inc
